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ABSTRACT	  	  
Purpose:	  Recent	   studies	  have	  highlighted	  significant	  variations	   in	   the	  management	  
of	  recent	  onset	  sustained	  atrial	   fibrillation	  (AF).	  Here,	  we	  aim	  to	  provide	  a	  succinct	  
and	  clear	  management	  algorithm	  for	  physicians	  managing	  patients	  with	  recent	  onset	  
sustained	  AF.	  
	  
Methods:	   We	   performed	   a	   comprehensive	   search	   of	   the	   literature	   on	   the	  
management	   of	   recent	   onset	   sustained	   AF	   with	   focus	   on	   studies	   reporting	  
cardioversion	  of	  AF,	  anti-­‐arrhythmic	  agents	  and	  anticoagulation.	  We	  also	   reviewed	  
recent	  practice	  guidelines	  on	  AF	  management.	  
	  
Findings:	   This	   review	   provides	   a	   guide	   on	   a	   tailored	   management	   approach	   of	  
patients	   with	   recent	   onset	   sustained	   AF.	   Following	   initial	   detailed	   clinical	  
assessment,	  optimal	  rate	  and	  rhythm	  control	  options	  can	  be	  provided	  depending	  on	  
hemodynamic	  stability,	  duration	  of	  AF	  episode	  and	  AF	  stroke	  risk.	  Issues	  surrounding	  
electrical	   and	   pharmacological	   cardioversion	   were	   discussed	   in	   detail.	   We	  
emphasized	   the	   importance	   of	   thromboembolic	   risk	   assessment	   and	   appropriate	  
anticoagulation	   surrounding	   the	   point	   of	   cardioversion.	   	   Last,	   we	   highlighted	   the	  
need	  for	  appropriate	  specialized	  follow-­‐up	  care	  following	  acute	  AF	  management.	  	  
	  
Implications:	  Despite	  the	  highly	  heterogeneous	  clinical	  presentations,	  management	  
of	   recent	   onset	   sustained	   AF	   must	   include	   stroke	   risk	   assessment,	   appropriate	  
anticoagulation	  and	  follow-­‐up	  care	  in	  all	  patients	  beyond	  optimum	  rate	  and	  rhythm	  
control	  strategies.	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INTRODUCTION	  
Despite	   the	   tremendous	   advances	   made	   in	   cardiovascular	   medicine	   over	   the	   last	  
century,	   atrial	   fibrillation	   (AF)	   has	   emerged	   as	   a	   global	   epidemic	   in	   this	   new	  
millennium	   with	   enormous	   public	   health	   and	   economic	   burden.(1)	   The	   estimated	  
cost	  of	  AF	  is	  at	  least	  one	  percent	  of	  the	  healthcare	  budget	  in	  developed	  nations	  and	  
this	   figure	   is	   set	   to	   climb	   further	   with	   recent	   evidence	   of	   increasing	   AF	   related	  
hospitalizations.(1-­‐3)	   Optimal	   management	   of	   AF	   is	   essential	   given	   its	   association	  
with	   increased	   risk	   of	   stroke	   (3	   to	   5	   fold)	   as	   well	   as	   mortality	   (1.5	   to	   2	   fold).(1)	  
However,	  significant	  variations	  in	  the	  management	  of	  acute	  sustained	  AF	  have	  been	  
consistently	   identified	   among	   emergency	   physicians	   and	   cardiologists	   in	   different	  
countries.(4-­‐6)	  This	  is	  perhaps	  not	  surprising	  given	  the	  heterogeneity	  of	  the	  patient	  
population	  presenting	  with	  AF	  and	  the	  diversity	  of	  available	  treatment	  options.	  This	  
review	   is	   focused	  on	   the	  holistic	  management	  of	  AF	  with	   specific	   attention	   to	   the	  
pharmacological	   and	   non-­‐pharmacological	   strategies	   for	   treating	   recent	   onset	  
sustained	  AF	  as	  recommended	  in	  recent	  practice	  guidelines.	  (7-­‐9)	  
	  
AF:	  Tailored	  Management	  Approach	  
The	  primary	  goals	  of	  AF	  management	  are	   to	   reduce	   symptoms,	   improve	  quality	  of	  
life	  and	   lessen	  the	  associated	  morbidities	  such	  as	  heart	   failure	  and	  stroke.	  When	  a	  
patient	  presents	  with	  symptomatic	  acute	  AF,	   the	  focus	  of	  management	   is	  often	  on	  
effective	   rhythm	   and	   rate	   control.	   However,	   when	   managing	   the	   highly	  
heterogeneous	  group	  of	  patients	  with	  AF,	  the	  complexity	  of	  the	  arrhythmia	  requires	  
careful	  considerations	  beyond	  the	  paradigm	  of	   rate	  and	  rhythm	  control.	  A	   tailored	  
management	   approach	   is	   essential	   after	   careful	   clinical	   evaluation	  of	   the	   different	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aspects	   as	   outlined	   in	   Table	   1.	  Management	   strategy	   for	   the	   acute	   AF	   episode	   is	  
often	  undertaken	  with	  consideration	  of	  the	  patient’s	  preferences.	  	  	  
	  
Recommended	  management	  of	  acute	  sustained	  AF	  
Approximately	   50%	   of	   acute	   AF	   episodes	   will	   terminate	   spontaneously	   within	   24	  
hours	   in	   the	   absence	   of	   secondary	   causes	   of	   AF.(10)	   If	   there	   is	   an	   identifiable	  
precipitant	   for	   the	  acute	  AF	  episode,	   treatment	  of	   the	  underlying	  condition	  will	  be	  
helpful	  in	  the	  management	  of	  the	  arrhythmia.	  In	  patients	  with	  more	  persistent	  form	  
of	  AF	  whereby	  previous	  cardioversion	  attempts	  have	  failed	  and	  rhythm	  control	  has	  
been	   abandoned,	   the	   focus	   of	   acute	   management	   should	   be	   on	   adequate	   rate	  
control	   and	   anticoagulation	   to	   prevent	   thromboembolic	   complications.	   Figure	   1	  
outlines	   our	   recommendations	   for	   managing	   patients	   presenting	   with	   acute	  
sustained	  AF.	  The	  key	  factors	  to	  consider	  are:	  hemodynamic	  stability,	  duration	  of	  AF	  
episode,	   thromboembolic	   risk	   stratification	   and	   anticoagulation	   management.	   In	  
general,	  they	  fall	  into	  four	  different	  groups	  as	  detailed	  below:	  	  
	  	  
I.	  Hemodynamically	  stable	  AF	  with	  onset	  <48	  hours	  
Initial	  rate	  control	  strategy	  can	  be	  implemented	  in	  those	  who	  are	  hemodynamically	  
stable,	  aiming	  for	  a	  target	  resting	  heart	  rate	  of	  <100	  bpm	  (Table	  2).	  Commonly	  used	  
rate	  control	  agents	  include	  beta-­‐blockers	  (e.g.	  metoprolol)	  and	  non-­‐dihydropyridine	  
calcium	   channel	   blockers	   (e.g.	   diltiazem	   or	   verapamil).	   In	   general,	   digoxin	   is	   used	  
only	   as	   a	   second	   line	   agent	   due	   to	   lower	   efficacy	  with	   slower	  onset	   of	   action	   and	  
poor	  heart	  rate	  control	  during	  exertion.	  Intravenous	  magnesium	  is	  less	  effective	  than	  
beta-­‐blockers	   or	   calcium	   channel	   blockers	   for	   rate	   control	   in	   patients	   with	   acute	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onset	  AF	  from	  meta-­‐analysis	  of	  randomized	  controlled	  trials	  although	  overall	  patient	  
numbers	  were	   low.(11)	   The	  use	  of	   intravenous	  magnesium	   is	  not	   a	   recommended	  
strategy	   in	   current	   practice	   guidelines.(7-­‐9)	   In	   patients	   with	   low	   stroke	   risk	   and	  
improved	   symptoms	   following	   good	   rate	   control,	   one	   possible	   strategy	   is	   to	  
discharge	   the	   patient	   on	   rate	   control	   medications	   with	   follow-­‐up	   the	   next	   day	  
(within	  48	  hours	  of	  AF	  onset)	  for	  cardioversion	  if	  AF	  persists.	  	  In	  those	  who	  are	  highly	  
symptomatic	   or	   those	   with	   inadequate	   rate	   control,	   cardioversion	   with	   drugs	   or	  
direct-­‐current	  can	  be	  considered	   if	   the	  patient	  has	  a	   low	   thromboembolic	   risk	  and	  
the	   onset	   of	   AF	   was	   within	   48	   hours.	   However,	   if	   the	   patient	   has	   increased	  
thromboembolic	   risk	   (CHA2DS2-­‐VASc	   score	   >1),	   effective	   peri-­‐cardioversion	  
anticoagulation	  is	  required	  followed	  by	  subsequent	  long-­‐term	  anticoagulation.(9,12)	  
This	  recommendation	  is	  in	  keeping	  with	  recent	  data	  from	  a	  large	  Finnish	  multicenter	  
cohort	   study	   showing	   that	   age,	   female	   sex,	   heart	   failure	   and	   diabetes	   were	  
independent	  predictors	  of	  thromboembolic	  complications	  following	  cardioversion	  of	  
acute	  AF	  with	  <48	  hours	  duration.(13)	  In	  that	  study,	  the	  highest	  thromboembolic	  risk	  
was	  in	  those	  with	  both	  heart	  failure	  and	  diabetes	  (9.8%),	  as	  compared	  to	  those	  with	  
age	  <60	  years	  and	  without	  heart	  failure	  (0.2%).(13)	  	  
	  
II.	  Hemodynamically	  stable	  AF	  with	  onset	  >48	  hours	  or	  unknown	  duration	  
Patients	  with	  AF	  lasting	  more	  than	  48	  hours	  or	  of	  unknown	  duration	  have	  increased	  
risk	  of	  left	  atrial	  thrombus	  formation	  rendering	  cardioversion	  (chemical	  or	  electrical)	  
unsafe.	  Therefore,	  the	  mainstay	  of	  initial	  therapy	  is	  to	  aim	  for	  good	  ventricular	  rate	  
control	   of	   <100bpm	   at	   rest	   (Table	   2).	   Cardioversion	   can	   be	   attempted	   in	   these	  
patients	   only	   with	   therapeutic	   anticoagulation	   for	   at	   least	   3	   weeks	   prior	   and	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continued	   for	   at	   least	   4	  weeks	   after.	   However,	   transesophageal	   echocardiography	  
guided	   cardioversion	   can	   be	   facilitated	   in	   the	   absence	   of	   left	   atrial	   and	   left	   atrial	  
appendage	   thrombus.(14)	   In	   this	   instance,	   it	   is	   essential	   that	   effective	   peri-­‐
cardioversion	  anticoagulation	  is	  commenced	  and	  maintained	  for	  at	  least	  four	  weeks	  
after	  to	  reduce	  new	  thrombus	  formation	  due	  to	  atrial	  stunning	  following	  restoration	  
of	   sinus	   rhythm.(15,16)	   Importantly,	   the	   effect	   of	   atrial	   stunning	   is	   not	   limited	   to	  
those	   who	   underwent	   electrical	   cardioversion	   with	   documented	   negative	   atrial	  
inotropic	   effect	   seen	   in	   those	   treated	  with	   anti-­‐arrhythmic	   drugs.(17)	   For	   patients	  
with	   increased	   thromboembolic	   risk,	   oral	   anticoagulation	   would	   need	   to	   be	  
maintained	  long-­‐term.	  
	  
III.	  Hemodynamically	  compromised	  AF	  	  
A	  small	  proportion	  of	  patients	  with	  acute	  AF	  may	  be	  hemodynamically	  compromised	  
thereby	   necessitating	   urgent	   cardioversion.	   The	   practicality	   of	   administrating	   peri-­‐
cardioversion	  anticoagulation	  will	  depend	  on	  the	  urgency	  of	   the	  situation.	   In	  some	  
cases,	  this	  may	  only	  be	  feasible	  following	  stabilization	  of	  the	  patient	  with	  restoration	  
of	   sinus	   rhythm.	   The	   recommendation	   is	   to	   administer	   anticoagulation	   as	   soon	   as	  
possible.(9)	   The	  duration	  of	  AF	   episode	   and	   thromboembolic	   risk	   of	   the	   individual	  
patient	  will	  guide	  long-­‐term	  anticoagulation	  strategy.	  	  
	  
IV.	  Recurrent	  hemodynamically	  stable	  AF	  
In	  a	  select	  group	  of	  patients	  with	  structurally	  normal	  heart	  and	   frequent	   recurrent	  
symptomatic	  AF	  without	  hemodynamic	  compromise,	  a	  “pill-­‐in-­‐the-­‐pocket”	  strategy	  
can	   be	   considered	   in	   the	   outpatient	   setting	   to	   reduce	   emergency	   room	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presentations	  and	  hospitalizations.(18)	  However,	  it	  is	  important	  to	  first	  establish	  the	  
safety	   of	   this	   approach	   with	   initial	   electrocardiographic	   monitoring	   to	   ensure	  
tolerability	   without	   pro-­‐arrhythmia	   effects	   or	   significant	   bradycardia	   following	   AF	  
termination.	   This	   strategy	   involves	   a	   Class	   IC	   anti-­‐arrhythmic	   drug	   	   (flecainide	   or	  
propafenone)	   always	   administered	   in	   conjunction	   with	   a	   rate-­‐slowing	   drug	   (beta-­‐
blocker	   or	   non-­‐dihydropyridine	   calcium	   channel	   blocker)	   to	   prevent	   1:1	   rapid	  
ventricular	  response	  during	  atrial	  flutter.(18-­‐20)	  The	  safety	  of	  this	  approach	  can	  also	  
be	  enhanced	  with	  careful	  selection	  of	  patients	  by	  avoiding	  usage	  in	  the	  very	  elderly	  
group	   (>70	   years	   old)	   as	   in-­‐hospital	   intravenous	   administration	   may	   not	   predict	  
future	  adverse	  events	  with	  oral	  pill-­‐in-­‐the-­‐pocket	  strategy.(21)	  
	  
	  
Cardioversion	  of	  AF:	  Electrical	  vs.	  Pharmacological	  
When	   rhythm	   control	   is	   desired,	   several	   factors	   will	   need	   to	   be	   considered	  when	  
choosing	  between	  electrical	  and	  pharmacological	  approaches.	  Recent	  data	  from	  the	  
prospective	   international	   multi-­‐center	   RHYTHM-­‐AF	   observational	   study	  
demonstrated	  a	  90%	  success	  rate	  with	  electrical	  cardioversion	  as	  compared	  to	  69%	  
with	  pharmacological	   cardioversion.(22)	  Both	  modes	  of	   cardioversion	   are	   safe	   and	  
effective	   with	   very	   low	   rate	   of	   complications	   as	   reported	   in	   the	   RHYTHM-­‐AF	  
study.(22)	   However,	   under-­‐treatment	   and	   over-­‐treatment	   with	   anticoagulation	  
therapy	  has	  also	  been	   identified.(23)	  Appropriate	  assessment	  of	  stroke	  risk	  and	  AF	  
duration	  must	  be	  undertaken	  in	  all	  patients	  regardless	  of	  the	  mode	  of	  cardioversion.	  
	  
Electrical	  Cardioversion	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Although	  electrical	  cardioversion	  has	  a	  higher	  success	  rate	  in	  restoring	  sinus	  rhythm,	  
it	   requires	   sedation	   or	   a	   light	   anesthesia	   and	   hence	   best	   performed	   in	   the	   post-­‐
absorptive	   state	   in	   patients	   who	   are	   hemodynamically	   stable.	   A	   biphasic	   external	  
defibrillator	   is	   preferred	   over	   older	   monophasic	   devices	   for	   greater	   efficacy	   of	  
cardioversion	  while	  requiring	  fewer	  shocks	  and	  at	   lower	  delivered	  energy	  with	   less	  
risk	  of	  dermal	   injury.(24)	  Further,	  synchronized	  higher	  shock	  energy	  level	  (biphasic:	  
150-­‐200J;	  monophasic:	   360J)	   is	   recommended	   to	   ensure	   higher	   initial	   success	   and	  
reduce	   the	   need	   for	   repeated	   shocks.(25,26)	   Placement	   of	   the	   defibrillation	  
electrode	  pads	  in	  the	  antero-­‐posterior	  position	  has	  been	  shown	  to	  be	  more	  effective	  
than	  in	  the	  antero-­‐lateral	  position.(27)	  Other	  strategies	  that	  may	  enhance	  success	  of	  
electrical	  cardioversion	  include	  application	  of	  pressure	  on	  the	  defibrillation	  electrode	  
pads	  to	  improve	  energy	  transfer	  and	  pre-­‐treatment	  with	  anti-­‐arrhythmic	  drugs.	  
	  
Apart	  from	  the	  inherent	  risk	  of	  thromboembolism	  with	  cardioversion,	  complications	  
specific	   to	   electrical	   cardioversion	   also	   include	   risk	  of	   sedation	  or	   light	   anesthesia;	  
bradyarrhythmias	  especially	  in	  those	  with	  co-­‐existing	  sinus	  node	  disease;	  ventricular	  
arrhythmias	  especially	   in	  those	  with	  hypokalemia,	  digitalis	  toxicity;	  delivery	  of	  non-­‐
synchronized	  shock;	  and	  skin	  burns	  or	  irritation	  especially	  in	  those	  needing	  multiple	  
shocks.	  On	   the	  whole,	  electrical	   cardioversion	  has	  been	  shown	   to	  be	  effective	  and	  
safe	   in	   prospective	   registry	   data	   showing	   acute	   fatal	   complication	   rate	   of	   0.1%	  
(death,	   thromboembolic	   event,	   heart	   failure,	   major	   bleeding,	   bradycardia	   and	  
hypotension)	  within	  first	  5	  days	  of	  cardioversion.(22)	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Pharmacological	  Cardioversion	  
Availability	   of	   anti-­‐arrhythmic	   drugs	   commonly	   used	   for	   pharmacological	  
cardioversion	  of	  AF	  may	  vary	  by	  country	  or	  region.	  These	  agents	  can	  be	  administered	  
orally	   or	   intravenously	   under	  medical	   supervision	  with	   continuous	   ECG	  monitoring	  
and	   temporary	   pacing	   capability	   due	   to	   the	   likelihood	   of	   proarrhythmic	   events.	  
Recent	   prospective	   observational	   data	   suggests	   intravenous	   administration	   of	  
antiarrhythmic	  agents	  has	  slightly	  superior	  efficacy	  with	  shorter	  time	  to	  conversion	  
as	  compared	  to	  oral	  route.(22)	  However,	  several	  others	  have	  shown	  little	  difference	  
in	   overall	   conversion	   rate	   between	   routes	   of	   administration	   for	   amiodarone,	  
flecainide	   and	   propafenone.(20,22,28-­‐30)	   Table	   3	   presents	   a	   summary	   of	   the	  
commonly	   used	   agents	   for	   conversion	   of	   AF.	   The	   clinical	   comorbidities	   of	   the	  
individual	   patient	   must	   be	   considered	   with	   the	   potential	   adverse	   drug	   effects	   to	  
guide	  selection	  of	  appropriate	  anti-­‐arrhythmic	  agent.	  	  Patients	  with	  structural	  heart	  
abnormalities	   including	   significant	   left	   ventricular	   hypertrophy,	   heart	   failure	   and	  
coronary	   artery	   disease	   have	   more	   limited	   options	   as	   Class	   IC	   agents	   are	  
contraindicated.	  Other	  factors	  to	  consider	  include	  baseline	  QT	  interval	  and	  patient’s	  
renal	  function.	  	  
	  
Limited	  studies	  with	  small	  sample	  sizes	  have	  directly	  compared	  the	  efficacy	  of	  anti-­‐
arrhythmic	   agents	   to	   placebo	   or	   other	   drugs	   in	   converting	   acute	   AF.(31)	  
Contemporary	   real	   life	   data	   suggests	   superior	   efficacy	   of	   Class	   IC	   agents	   to	  
amiodarone	  which	  did	  not	  seem	  to	  be	  better	  than	  rate	  control	  agents	  in	  accelerating	  
conversion	  of	  AF.(22)	  Intravenous	  magnesium	  is	  not	  recommended	  for	  conversion	  of	  
acute	   onset	   AF	   due	   to	   limited	   efficacy.(11)	  More	   recent	   studies	   have	   shown	   that	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vernakalant,	  a	  novel	  atrial	  selective	  anti-­‐arrhythmic	  agent,	  demonstrates	  more	  rapid	  
AF	  conversion	  as	  compared	  to	  amiodarone	  and	  Class	  IC	  agents.(32-­‐34)	  Nevertheless,	  
the	   choice	   of	   agents	   for	   conversion	   of	   AF	   must	   be	   based	   on	   patient	   safety,	  
contraindications,	  adverse	  effects	  and	  availability.	  	  
	  
Thromboembolic	  Risk	  Assessment	  and	  Anticoagulation	  Therapy	  
Assessing	  thromboembolic	  risk	  and	  the	  need	  for	  anticoagulation	  therapy	  is	  crucial	  in	  
the	  management	  of	  patients	  with	  AF.	  The	  clinical	  encounter	  when	  patients	  present	  
with	  acute	  sustained	  AF	  is	  no	  exception.	  Recent	  real	  world	  data	  has	  highlighted	  the	  
gap	   in	   current	   management	   with	   both	   under-­‐	   and	   over-­‐treatment	   with	  
anticoagulation.(23)	  Assessment	  of	  stroke	  risk	  must	  be	  carried	  out	  using	  established	  
risk	  score	  such	  as	  the	  CHA2DS2-­‐VASc	  score	  [congestive	  heart	  failure	  or	  left	  ventricular	  
dysfunction,	   hypertension,	   age	   ≥75	   (doubled),	   diabetes,	   stroke	   (doubled),	   vascular	  
disease,	  age	  65–74	  and	  sex	  category	  (female)].(35)	  	  
	  
Recently,	  several	  novel	  oral	  anticoagulants	  have	  become	  available	  as	  alternatives	  to	  
vitamin	  K	  antagonist,	  warfarin.	  These	  agents	  either	  inhibit	  thrombin	  (dabigatran)	  or	  
Factor	   Xa	   (rivaroxaban	   or	   apixaban)	   directly.	   They	   have	   been	   shown	   to	   be	   non-­‐
inferior	  to	  warfarin	  and	  in	  some	  instances,	  superior	  results	  for	  preventing	  stroke	  and	  
systemic	   embolism	   as	   well	   as	   less	   hemorrhagic	   strokes	   without	   increased	   risk	   of	  
major	   bleeding.(36)	   However,	   the	   safety	   and	   efficacy	   data	   on	   the	   usage	   of	   these	  
novel	  agents	  at	  the	  time	  of	  cardioversion	  are	  derived	  from	  patients	  who	  are	  already	  
on	   long-­‐term	   therapy	   (more	   than	   3	  weeks).(37-­‐39)	  However,	   it	   is	   likely	   that	   these	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agents	  will	  provide	  at	   least	  the	  same	  protection	  for	  thromboembolic	  complications	  
as	  warfarin	  surrounding	  cardioversion	  of	  AF.	  	  	  
	  
Follow-­‐up	  After	  Acute	  AF	  Management	  
The	  complexity	  of	  AF	  management	  and	  heterogeneity	  in	  the	  patients	  presenting	  with	  
acute	   sustained	   AF	   demands	   specialized	   care	   following	   acute	   AF	   care.	   This	   is	  
particularly	  so	  for	  patients	  with	  newly	  diagnosed	  AF	  whereby	  comprehensive	  AF	  risk	  
factor	  assessment,	  ongoing	  patient	  education	  and	  anticoagulation	  management	  are	  
warranted.	  Referral	   to	  heart	  rhythm	  specialists	  or	  cardiologists	  with	   interests	   in	  AF	  
management	   is	  highly	  recommended	  for	  ongoing	  care.	  A	  proportion	  of	  AF	  patients	  
may	  subsequently	  require	  and	  benefit	  from	  catheter	  ablation	  therapy	  that	  has	  been	  
shown	   to	   be	   an	   effective	   and	   durable	   long-­‐term	   option	   with	   decreasing	   peri-­‐
procedural	   complications.(40-­‐42)	   Further,	   specialized	   nurse-­‐led	   guidelines	   based	  
chronic	  care	  of	  AF	  patients	  has	  been	  shown	  to	  reduce	  hospitalizations	  and	  improve	  
outcomes.(43)	  	  
	  
Clinicians	   must	   recognize	   that	   AF	   is	   a	   consequence	   of	   ‘atrial	   myopathy’	   with	  
increasing	   number	   of	   novel	   risk	   factors	   being	   identified	   in	   recent	   years	   including:	  
pericardial	   fat,	  prehypertension,	  widened	  pulse	  pressure,	  aortic	   stiffness	  and	   sleep	  
apnea.(44-­‐48)	  Indeed,	  there	  has	  been	  a	  recent	  proposal	  for	  avoiding	  the	  use	  of	  the	  
term	  ‘lone	  AF’.(49)	  Therefore,	  the	  underlying	  modifiable	  risk	  factors	  must	  be	  actively	  
targeted	  to	  reduce	  the	  arrhythmogenic	  substrate	  and	  AF	  burden	  in	  patients	  with	  this	  
debilitating	  arrhythmia.(50)	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CONCLUSIONS	  
This	   review	   details	   the	   options	   for	   tailored	   treatment	   approach	   in	   patients	   with	  
recent	   onset	   sustained	   AF.	   In	   addition	   to	   the	   rate	   and	   rhythm	   control	   aspects	   of	  
management,	   it	   highlights	   the	   need	   to	   assess	   stroke	   risk	   in	   all	   AF	   patients	   and	  
arrange	   appropriate	   follow-­‐up	   care	   following	   the	   acute	   episode	   to	   optimize	   long-­‐
term	  outcomes.	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Table	  1:	  Initial	  Assessments	  of	  Patients	  with	  Acute	  AF	  
	  
Initial	  Assessments	  of	  Patients	  with	  Acute	  AF	  
AF	  History	   Current	  episode:	  known	  onset?	  	  within	  48	  hours?	  symptomatic?	  
Previous	  AF:	  
AF	  Type:	  Paroxysmal	  vs.	  Persistent	  vs.	  Chronic	  
AF	  therapy:	  electrical	  cardioversion?	  anti-­‐arrhythmic	  drugs,	  ablation	  
Anticoagulation	  strategy	  
	  




Coronary	  artery	  disease	  
Valvular	  heart	  disease	  




Infiltrative	  heart	  disease	  
Familial	  AF	  
Triggers	  for	  AF:	  
Systemic	  Infection	  or	  sepsis	  (e.g.	  pneumonia)	  
Inflammation	  (e.g.	  pericarditis,	  myocarditis)	  
Atrial	  ischemia	  (e.g.	  coronary	  syndrome)	  
Endocrine	  (e.g.	  thyrotoxicosis)	  
Drugs	  (e.g.	  caffeine,	  alcohol)	  
Electrolyte	  disturbances	  
Neurogenic	  (e.g.	  stroke,	  intra-­‐cranial	  bleed)	  
Left	  atrial	  strain	  (e.g.	  pulmonary	  embolism,	  
acute	  hypertension,	  acute	  heart	  failure)	  
Post-­‐operative	  state	  	  




Use	  CHA2DS2-­‐VASc	  score	  to	  determine	  need	  for	  long-­‐term	  oral	  
anticoagulation	  
	  
Clinical	  Evaluation	   Hemodynamic	  stability	  






Investigations	   12-­‐lead	  ECG:	  ischemia,	  pre-­‐excitation	  
Biochemistry	  
Full	  blood	  count	  
Inflammatory	  markers	  
Thyroid	  function	  test	  
Cardiac	  enzymes	  	  
Chest	  x-­‐ray	  
